Immune Netw.  2019 Dec;19(6):e43. 10.4110/in.2019.19.e43.

Evaluating Antitumor Activity of Kiatomab by Targeting Cancer Stem Cell-Specific KIAA1114 Antigen in Mice

• Kim SW
• Park HW
• Kim H
• Lee S
• Choi SY
• Park Y
• Lee SW

• KMID: 2466613
• DOI: http://doi.org/10.4110/in.2019.19.e43

Abstract

A full-length translational product of the trophinin gene, KIAA1114, is a distinctive marker of cancer stem cells in human hepatocellular carcinoma, and a mAb, Kiatomab, is specific to KIAA1114 antigen. In this study, we addressed the therapeutic potential of Kiatomab for treating both metastatic and solid tumors in mouse models. Kiatomab recognizes the linear epitope of KIAA1114, which is expressed on cell surfaces of various murine cancer cell lines. Kiatomab treatment induced potent antitumor responses in pulmonary metastasis models. Antitumor activity was mediated by the fragment crystallizable portion of Kiatomab and dependent on the host immune system. The use of Kiatomab alone as an antitumor therapy was ineffective in solid tumor models. However, in combination with cyclophosphamide, or by switching the isotype of the mAb, improved antitumor effects of Kiatomab were observed. These results suggest that Kiatomab can be used as a novel mAb for cancer immunotherapy.

Keyword

Kiatomab; KIAA1114; Tumors; Cancer stem cells; Cancer immunotherapy; Metastasis

MeSH Terms

Animals
Carcinoma, Hepatocellular
Cell Line
Cyclophosphamide
Humans
Immune System
Immunotherapy
Mice*
Neoplasm Metastasis
Neoplastic Stem Cells
Cyclophosphamide